JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirshner, N.
Right arrow Articles by Kamin, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirshner, N.
Right arrow Articles by Kamin, D. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 141, Issue 3, 285-289, 1963
Copyright © 1963 by American Society for Pharmacology and Experimental Therapeutics

INHIBITION OF DOPAMINE UPTAKE IN VITRO BY RESERPINE ADMINISTERED IN VIVO

Norman Kirshner 1, Mary Rorie 1, and Dorothy L. Kamin 1

1 Departments of Biochemistry and Experimental Surgery, Duke University Medical Center, Durham, North Carolina

The accumulation of dopamine-C14 and its conversion to norepinephrine was measured in adrenal gland homogenates of 29 control cats and 28 cats injected with 2.5 mg of reserpine intraperitoneally. It was observed that up to 2 days after the injection of reserpine the total catecholamine content of the adrenal gland was 70% depleted and its ability to accumulate dopamine was inhibited by about 90%. By the third day the catecholamine content and the ability to accumulate and convert dopamine to norepinephrine began to recover and at the end of 2 weeks were at normal levels. These observations are interpreted to support the hypothesis that reserpine causes a depletion of the catecholamine stores by inhibiting the transport of dopamine into the granules and there its subsequent conversion to norepinephrine.

Submitted on March 25, 1963
Accepted on May 27, 1963




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. K. Mahata, N. R. Mahapatra, M. Mahata, T. C. Wang, B. P. Kennedy, M. G. Ziegler, and D. T. O'Connor
Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo: DEMONSTRATION BY A NOVEL TRANSGENIC PROMOTER/PHOTOPROTEIN REPORTER AND INHIBITION OF SECRETION AND TRANSCRIPTION BY THE CHROMOGRANIN A FRAGMENT CATESTATIN
J. Biol. Chem., August 22, 2003; 278(34): 32058 - 32067.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Mahata, S. K. Mahata, R. J. Parmer, and D. T. O'Connor
Vesicular Monoamine Transport Inhibitors: Novel Action at Calcium Channels to Prevent Catecholamine Secretion
Hypertension, September 1, 1996; 28(3): 414 - 420.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1963 by the American Society for Pharmacology and Experimental Therapeutics.